195 related articles for article (PubMed ID: 33207589)
1. Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection.
Gambichler T; Reuther J; Scheel CH; Susok L; Kern P; Becker JC
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207589
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in cancer patients with COVID-19.
Pan Y; Tan J; Li J; Li T; Li J; Cao Y; Yang L; Lin X; Li M; Liang X
Open Life Sci; 2023; 18(1):20220641. PubMed ID: 37426624
[TBL] [Abstract][Full Text] [Related]
3. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibition in COVID-19: risks and benefits.
Pezeshki PS; Rezaei N
Expert Opin Biol Ther; 2021 Sep; 21(9):1173-1179. PubMed ID: 33543652
[TBL] [Abstract][Full Text] [Related]
5. Management of immune checkpoint therapy for patients with cancer in the face of COVID-19.
Shen C; Li Q; Wei Y; Li Y; Li J; Tao J
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303577
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis.
Dumoulin DW; Gietema HA; Paats MS; Hendriks LEL; Cornelissen R
Front Oncol; 2020; 10():577696. PubMed ID: 33194697
[TBL] [Abstract][Full Text] [Related]
7. Cancer Patients Have a Higher Risk Regarding COVID-19 - and Vice Versa?
Geisslinger F; Vollmar AM; Bartel K
Pharmaceuticals (Basel); 2020 Jul; 13(7):. PubMed ID: 32640723
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
9. Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era.
Burgaletto C; Brunetti O; Munafò A; Bernardini R; Silvestris N; Cantarella G; Argentiero A
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921021
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis.
Qian W; Ye Y; Zuo L; Song T; Xu Q; Wang Y; Qian J; Tian Y
Immunotherapy; 2021 Oct; 13(15):1271-1282. PubMed ID: 34431319
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity from immune checkpoint inhibitors.
Michel L; Rassaf T; Totzeck M
Int J Cardiol Heart Vasc; 2019 Dec; 25():100420. PubMed ID: 31517036
[TBL] [Abstract][Full Text] [Related]
12. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 Outcomes in Stage IV Cancer Patients Receiving Immune Checkpoint Inhibitors.
Guo M; Liu J; Zhou S; Yu J; Ahmed Z; Ahmad S; Manoucheri M; Socinski MA; Mekhail T; Hsu V
SN Compr Clin Med; 2022; 4(1):193. PubMed ID: 36043120
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.
Patel NS; Oury A; Daniels GA; Bazhenova L; Patel SP
Oncologist; 2018 Oct; 23(10):1236-1241. PubMed ID: 29769383
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease.
Weingarden AR; Rubin SJS; Gubatan J
World J Gastrointest Oncol; 2021 Aug; 13(8):772-798. PubMed ID: 34457186
[TBL] [Abstract][Full Text] [Related]
16. Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
Gkiozos I; Kopitopoulou A; Kalkanis A; Vamvakaris IN; Judson MA; Syrigos KN
J Thorac Oncol; 2018 Aug; 13(8):1076-1082. PubMed ID: 29763666
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Suzman DL; Pelosof L; Rosenberg A; Avigan MI
Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.
Zhou YW; Zhu YJ; Wang MN; Xie Y; Chen CY; Zhang T; Xia F; Ding ZY; Liu JY
Front Pharmacol; 2019; 10():1350. PubMed ID: 31849640
[TBL] [Abstract][Full Text] [Related]
19. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
20. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Klebanov N; Pahalyants V; Murphy WS; Theodosakis N; Zubiri L; Klevens RM; Kwatra SG; Lilly E; Reynolds KL; Semenov YR
Oncologist; 2021 May; 26(5):e898-e901. PubMed ID: 33783099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
